Intervention
Axl/Mer/CSF1R Inhibitor Q702
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 1 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
1 shownCommon conditions
Hematopoietic and Lymphatic System Neoplasm1Histiocytic Sarcoma1Malignant Histiocytosis1Peripheral T-Cell Lymphoma, Not Otherwise Specified1Primary Central Nervous System Lymphoma1Primary Cutaneous T-Cell Non-Hodgkin Lymphoma1Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm1Recurrent Chronic Lymphocytic Leukemia1Recurrent Chronic Myelomonocytic Leukemia1Recurrent Erdheim-Chester Disease1Recurrent Fibroblastic Reticular Cell Sarcoma1Recurrent Follicular Lymphoma1Recurrent Histiocytic Sarcoma1Recurrent Interdigitating Dendritic Cell Sarcoma1Recurrent Langerhans Cell Histiocytosis1Recurrent Lymphoplasmacytic Lymphoma1Recurrent Myelodysplastic Syndrome1Recurrent Myelofibrosis1Recurrent Rosai-Dorfman-Destombes Disease1Recurrent Small Lymphocytic Lymphoma1Recurrent Waldenstrom Macroglobulinemia1Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm1Refractory Chronic Lymphocytic Leukemia1Refractory Chronic Myelomonocytic Leukemia1Refractory Erdheim-Chester Disease1
Leading sponsors
Trial status mix
RECRUITING1
Phase mix
PHASE11
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.